Holen Sie sich die Stockscreener-App
0.2782
0.29%
-0.0008
Schlusskurs vom Vortag:
$0.279
Offen:
$0.2824
24-Stunden-Volumen:
246.87K
Relative Volume:
0.05
Marktkapitalisierung:
$3.73M
Einnahmen:
$142.00K
Nettoeinkommen (Verlust:
$-1.23M
KGV:
0.5974
EPS:
0.4657
Netto-Cashflow:
$-10.62M
1W Leistung:
-2.49%
1M Leistung:
-24.20%
6M Leistung:
-85.12%
1J Leistung:
-87.69%
1-Tages-Spanne:
$0.2753
$0.284
1-Wochen-Bereich:
$0.271
$0.2959
52-Wochen-Spanne:
$0.2625
$5.30
Vivosim Labs Inc Stock (VIVS) Company Profile
Firmenname
Vivosim Labs Inc
Sektor
Branche
Telefon
858-224-1000
Adresse
11555 SORRENTO VALLEY ROAD, SAN DIEGO
Compare VIVS vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
0.2782 | 3.72M | 142.00K | -1.23M | -10.62M | 0.4657 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-12-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-11-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-01-25 | Eingeleitet | Raymond James | Outperform |
| 2015-08-11 | Herabstufung | Cantor Fitzgerald | Buy → Hold |
| 2015-06-29 | Eingeleitet | Jefferies | Buy |
| 2015-06-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Vivosim Labs Inc Aktie (VIVS) Neueste Nachrichten
VivoSim Labs Faces Nasdaq Minimum Bid Price Deficiency - TipRanks
VivoSim Labs Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Warrants keep Esousa, Wachs’ VivoSim Labs (VIVS) stake under 10% - Stock Titan
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - Barchart.com
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as - openPR.com
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus - FinancialContent
VivoSim Labs (VIVS) seeks approval for reverse split, equity plan and warrant repricing - Stock Titan
VivoSim: Fiscal Q1 Earnings Snapshot - marketscreener.com
Oversold Stocks TOON, RMCF, PRSO, OFAL Offer Opportunity – See Why Inside - FinancialContent
VivoSim Labs Ord Shs (VIVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
$VIVS Load up 🔥🚀 - Moomoo
VivoSim Labs, INC. SEC Filing (Aug 11, 2026) - Stock Titan
VivoSim Labs (NASDAQ: VIVS) seeks approval for reverse split, warrant share issuance - Stock Titan
VivoSim Labs (VIVS) News Flow - Moomoo
VIVS PE Ratio & Valuation, Is VIVS Overvalued - Intellectia AI
VIVOSIM LABS Q1 2026 Earnings Preview: Recent $VIVS Insider Trading, Hedge Fund Activity, and More - Moomoo
Stock Splits Calendar for: - Yahoo! Finance Canada
VivoSim Labs regains Nasdaq compliance after cash infusion By Investing.com - Investing.com UK
VivoSim Labs Regains Nasdaq Compliance, Boosts Cash to $10.1M and Projects 500%+ Revenue Growth for 2027 - Minichart
VivoSim Labs regains Nasdaq compliance after cash infusion - Investing.com
🍋💦🍋💦💣🚀 - Moomoo
VivoSim Provides Financial and Listing Compliance Update - The Manila Times
VivoSim regains Nasdaq compliance after $10.1 million cash update - Quiver Quantitative
VivoSim Labs Regains Nasdaq Compliance After $6M Milestone and $4M Financing - TradingView
VivoSim reports 13.4M shares outstanding after July warrant exercises - Stock Titan
VivoSim Labs issues 9,896,718 shares on warrant exercises - Bitget
IPO Databook: VivoSim Labs (VIVS US)Jul 2026 - Smartkarma
VivoSim Labs Sets 2026 Annual Shareholder Meeting Date - The Globe and Mail
VivoSim Labs, Inc. Revenue Breakdown – NASDAQ:VIVS - TradingView
VivoSim Labs (VIVS) Dips 6.89% as Stock Tests Key Support at $0.40Straddle Setup - Vinanet
VIVS|VivoSim Labs Ord Shs|Price:0.413|Chg%:-0.037 - TradingKey
VivoSim Labs Addresses Nasdaq Listing Compliance Concerns - TipRanks
VIVS|VivoSim Labs Ord Shs|Price:0.282|Chg%:-0.035 - TradingKey
VivoSim Labs, Inc. (VIVS) Stock Price, News, Quote & History - Yahoo! Finance Canada
VivoSim Labs, Inc. (VIVS) stock price, news, quote and history - Yahoo Finance UK
VivoSim Labs (VIVS) Holds Steady Near Support at $0.45 Amid Low VolatilityFactor ETF Flow - dars.gov.et
VIVS Expands into China with First Commercial Sales - GuruFocus
VivoSim secures first commercial sales in China market By Investing.com - Investing.com South Africa
VivoSim secures first commercial sales in China market - Investing.com UK
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services - GlobeNewswire
VIVS Q4 2025 Earnings: Massive EPS Miss Sends Shares LowerOperating Income Trends - vinanet.vn
VivoSim Labs Raises $4 Million in At-the-Market Private Placement to Advance 3D Human Tissue Models for Drug Safety Testing 1 – Minichart - Minichart
VivoSim Labs Announces $4 Million Private Placement Financing - TipRanks
VivoSim Labs Prices $4.0 Million Private Placement and Amends Legacy Armistice Warrants - TradingView
VivoSim prices $0.85 warrants in $4 million private placement - Bitget
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor - Sahm
Why is VivoSim Labs stock falling Thursday? - MSN
VivoSim raises $4M in private placement from single healthcare investor - Dealroom
VivoSim Labs raises $4M in private placement - Investing.com India
VivoSim Labs prices USD 4 million private placement at USD 0.85 per share - Bitget
VivoSim Labs raises $4M in private placement By Investing.com - Investing.com Nigeria
Finanzdaten der Vivosim Labs Inc-Aktie (VIVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):